Gesundheitsökonomische Aspekte chronischer Infektionskrankheiten am Beispiel der chronischen Hepatitis C

[1]  M. Gold.  Cost-effectiveness in health and medicine , 2016 .

[2]  M. Bullinger,et al.  Using competence network collaboration and decision-analytic modeling to assess the cost-effectiveness of interferon α-2b plus ribavirin as initial treatment of chronic hepatitis C in Germany , 2005, The European Journal of Health Economics.

[3]  P. Ritvo,et al.  Potential cost-effectiveness of a preventive hepatitis C vaccine in high risk and average risk populations in Canada. , 2005, Vaccine.

[4]  N. Waugh,et al.  Clinical- and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: A systematic review and economic evaluation , 2005, International Journal of Technology Assessment in Health Care.

[5]  N. Waugh,et al.  Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. , 2004, Health technology assessment.

[6]  Robert Koch-Institut.  Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2002 , 2003 .

[7]  Uwe Siebert,et al.  When should decision-analytic modeling be used in the economic evaluation of health care? , 2003, The European Journal of Health Economics, formerly: HEPAC.

[8]  John B. Wong,et al.  Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C , 2003 .

[9]  Dieter Häussinger,et al.  Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. , 2002, The New England journal of medicine.

[10]  J. Brazier,et al.  The estimation of a preference-based measure of health from the SF-36. , 2002, Journal of health economics.

[11]  A. McCullough,et al.  Surprisingly Small Effect of Antiviral Treatment in Patients with Hepatitis C , 2002, Annals of Internal Medicine.

[12]  L. Kjaergard,et al.  Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials , 2001, BMJ : British Medical Journal.

[13]  Kenneth Koury,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[14]  M. Höhne,et al.  Hepatitis C – Epidemiologie und Prävention , 2001, Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz.

[15]  C. Gluud,et al.  A systematic review on interferon-alpha with or without ribavirin for interferon naive, non-responders, and relapsers with chronic hepatitis C , 2001 .

[16]  J. Wong,et al.  Estimating future hepatitis C morbidity, mortality, and costs in the United States. , 2000, American journal of public health.

[17]  J. Wong,et al.  Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 2000, The American journal of gastroenterology.

[18]  S. Pauker,et al.  Cost-effectiveness of 24 or 48 weeks of interferon α-2b alone or with ribavirin as initial treatment of chronic hepatitis c , 2000, American Journal of Gastroenterology.

[19]  M. Weinstein.  High-Priced Technology Can Be Good Value for Money , 1999, Annals of Internal Medicine.

[20]  H. T. Head,et al.  Global surveillance and control of hepatitis C , 1999 .

[21]  M Emmelin,et al.  How many lives is equity worth? A proposal for equity adjusted years of life saved. , 1998, Journal of epidemiology and community health.

[22]  J B Wong,et al.  Estimates of the Cost-Effectiveness of a Single Course of Interferon-2b in Patients with Histologically Mild Chronic Hepatitis C , 1997, Annals of Internal Medicine.

[23]  D. Feeny,et al.  Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.

[24]  M. Johannesson,et al.  A note on the estimation of the equity-efficiency trade-off for QALYs. , 1996, Journal of health economics.

[25]  M. Rosén,et al.  An epidemiological approach towards measuring the trade-off between equity and efficiency in health policy. , 1996, Health policy.

[26]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[27]  A. Wagstaff.  QALYs and the equity-efficiency trade-off. , 1991, Journal of health economics.

[28]  F. Sonnenberg,et al.  Myocardial revascularization for chronic stable angina. Analysis of the role of percutaneous transluminal coronary angioplasty based on data available in 1989. , 1990, Annals of internal medicine.

[29]  M. Drummond,et al.  Health Care Technology: Effectiveness, Efficiency and Public Policy@@@Methods for the Economic Evaluation of Health Care Programmes , 1988 .

[30]  Neil Kaplowitz,et al.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis , 1981, Hepatology.

[31]  M. Manns,et al.  Antiviral treatment initiation costs in chronic hepatitis C. , 2005, Gut.

[32]  F. Sassi,et al.  Equity and the economic evaluation of healthcare. , 2001, Health technology assessment.